Autoantibodies in XXXX .

@entity1 @entity146 @entity1252 @entity1701 @entity4163 @entity715 @entity12319
The American College of Rheumatology presented a consensus document in 1999 proposing the classification of 19 different syndromes defined by neurological and @entity146 manifestations of @entity1252 ( @entity1252 ). The detection of autoantibodies in patient's serum or cerebrospinal fluid has not been used as diagnostic markers for the proposed @entity12319 as their disease associations remain highly contentious. Autoantibodies detected in the serum and/or cerebrospinal fluid, that have been reported to segregate with @entity1 presenting with @entity12319 include: (1) anti-neuronal antibodies, (2) brain-lymphocyte cross-reactive antibodies, (3) anti-ribosomal P antibodies, (4) anti-phospholipid antibodies and (5) anti- @entity4163 antibodies. Tests for anti-neuronal, anti-brain-lymphocyte cross-reactive and anti- @entity4163 antibodies remain highly specialized whereas tests for ribosomal P antibodies and for antiphospholipid antibodies are currently routinely available in most diagnostic laboratories. Anti-ribosomal antibodies segregate with @entity1252 . Antiphospholipid P antibodies are markers for the @entity1701 . This syndrome may be associated with another disease, commonly @entity1252 . In this setting, @entity146 manifestations in @entity1252 may arise as a consequence of @entity715 episodes involving the cerebral vasculature. There is a pressing need for antibodies to ribosomal P and to phospholipids to be standardized for routine diagnostic application. We conclude that the search for specific antibody marker(s) that can be applied for the routine laboratory diagnosis for @entity12319 remains elusive.
